$3.89
+0.19 (+5.14%)
Open$3.74
Previous Close$3.70
Day High$3.90
Day Low$3.73
52W High$10.29
52W Low$3.22
Volume—
Avg Volume200.9K
Market Cap118.24M
P/E Ratio—
EPS$-1.75
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+789.7% upside
Current
$3.89
$3.89
Target
$34.61
$34.61
$23.82
$34.61 avg
$34.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 82.58M | 64.69M | 25.19M |
| Net Income | -56,031,658 | -39,502,187 | -2,467,246 |
| Profit Margin | -67.9% | -64.5% | -9.8% |
| EBITDA | -47,542,889 | -35,379,715 | -4,050,890 |
| Free Cash Flow | — | — | -1,532,934 |
| Rev Growth | +27.7% | +27.7% | +20.8% |
| Debt/Equity | 9.39 | 9.39 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |